adenine has been researched along with Melanoma in 20 studies
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we found that β-mangostin from seedcases of Garcinia mangostana inhibited α-melanocyte-stimulating hormone (α-MSH)-mediated melanogenesis in B16F10 melanoma cells and a three-dimensional human skin model." | 7.85 | Depigmentation of α-melanocyte-stimulating hormone-treated melanoma cells by β-mangostin is mediated by selective autophagy. ( Kim, KD; Lee, KW; Madhi, H; Oh, SS; Park, KH; Park, S; Ryu, HW; Yoo, J, 2017) |
| " In search of such a drug, we examined the efficacy of graveoline, a bioactive compound isolated from Ruta graveolens on skin melanoma A375 cells through the use of specific signaling cascades and their inhibitors." | 7.80 | Graveoline isolated from ethanolic extract of Ruta graveolens triggers apoptosis and autophagy in skin melanoma cells: a novel apoptosis-independent autophagic signaling pathway. ( Bishayee, K; Ghosh, S; Khuda-Bukhsh, AR, 2014) |
| "A group of 39 patients with malignant melanoma were treated with dacarbazine 1 g/m(2) i." | 7.70 | Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen. ( Braybrooke, JP; Crawley, JE; Harris, AL; Houlbrook, S; O'Byrne, KJ; Propper, DJ; Shuker, DE; Stratford, IJ; Talbot, DC, 2000) |
| "2DG/rotenone failed to increase proautophagic beclin-1 and autophagic flux in melanoma cells despite the activation of AMP-activated protein kinase (AMPK) and inhibition of mechanistic target of rapamycin complex 1 (mTORC1)." | 5.62 | 3-Methyladenine prevents energy stress-induced necrotic death of melanoma cells through autophagy-independent mechanisms. ( Bosnjak, M; Harhaji-Trajkovic, L; Kosic, M; Kravic-Stevovic, T; Mircic, A; Paunovic, V; Ristic, B; Stevanovic, D; Trajkovic, V, 2021) |
| " In this study, we found that β-mangostin from seedcases of Garcinia mangostana inhibited α-melanocyte-stimulating hormone (α-MSH)-mediated melanogenesis in B16F10 melanoma cells and a three-dimensional human skin model." | 3.85 | Depigmentation of α-melanocyte-stimulating hormone-treated melanoma cells by β-mangostin is mediated by selective autophagy. ( Kim, KD; Lee, KW; Madhi, H; Oh, SS; Park, KH; Park, S; Ryu, HW; Yoo, J, 2017) |
| " In search of such a drug, we examined the efficacy of graveoline, a bioactive compound isolated from Ruta graveolens on skin melanoma A375 cells through the use of specific signaling cascades and their inhibitors." | 3.80 | Graveoline isolated from ethanolic extract of Ruta graveolens triggers apoptosis and autophagy in skin melanoma cells: a novel apoptosis-independent autophagic signaling pathway. ( Bishayee, K; Ghosh, S; Khuda-Bukhsh, AR, 2014) |
| "We tested 17 malignant mucosal melanomas of the head and neck for the thymine (T)-->adenine (A) missense mutation at nucleotide 1796 in the BRAF gene using direct sequencing and a newly developed assay that uses a novel primer extension method (Mutector assay)." | 3.72 | Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites. ( Begum, S; Cohen, Y; Esche, C; Goldenberg, D; Lavie, O; Rosenbaum, E; Sidransky, D; Westra, WH, 2004) |
| "A group of 39 patients with malignant melanoma were treated with dacarbazine 1 g/m(2) i." | 3.70 | Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen. ( Braybrooke, JP; Crawley, JE; Harris, AL; Houlbrook, S; O'Byrne, KJ; Propper, DJ; Shuker, DE; Stratford, IJ; Talbot, DC, 2000) |
| "2DG/rotenone failed to increase proautophagic beclin-1 and autophagic flux in melanoma cells despite the activation of AMP-activated protein kinase (AMPK) and inhibition of mechanistic target of rapamycin complex 1 (mTORC1)." | 1.62 | 3-Methyladenine prevents energy stress-induced necrotic death of melanoma cells through autophagy-independent mechanisms. ( Bosnjak, M; Harhaji-Trajkovic, L; Kosic, M; Kravic-Stevovic, T; Mircic, A; Paunovic, V; Ristic, B; Stevanovic, D; Trajkovic, V, 2021) |
| "The prognosis for malignant melanoma is poor; therefore, new diagnostic methods and treatment strategies are urgently needed." | 1.39 | Characterization of phosphodiesterase 2A in human malignant melanoma PMP cells. ( Inui, M; Morita, H; Murata, T; Okumura, K; Shimizu, K; Tagawa, T, 2013) |
| "B16cOVA melanoma was implanted to TLR7 mice to evaluate the roles of stromal TLR7 on melanoma growth." | 1.37 | Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2. ( Carson, DA; Chan, M; Corr, M; Cottam, HB; Daniels, GA; Hayashi, T; Norton, JT; Tawatao, RI; Wu, CC; Yao, S, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 3 (15.00) | 29.6817 |
| 2010's | 12 (60.00) | 24.3611 |
| 2020's | 4 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ren, S | 1 |
| Wang, X | 2 |
| Song, J | 1 |
| Jin, G | 1 |
| Misek, SA | 1 |
| Newbury, PA | 1 |
| Chekalin, E | 1 |
| Paithankar, S | 1 |
| Doseff, AI | 1 |
| Chen, B | 1 |
| Gallo, KA | 1 |
| Neubig, RR | 1 |
| Zhang, L | 1 |
| Ji, Z | 1 |
| Zhang, J | 1 |
| Yang, S | 1 |
| Moschos, SJ | 1 |
| Eroglu, Z | 1 |
| Khushalani, NI | 1 |
| Kendra, KL | 1 |
| Ansstas, G | 1 |
| In, GK | 1 |
| Wang, P | 1 |
| Liu, G | 1 |
| Collichio, FA | 1 |
| Googe, PB | 1 |
| Carson, CC | 1 |
| McKinnon, K | 1 |
| Wang, HH | 1 |
| Nikolaishvilli-Feinberg, N | 1 |
| Ivanova, A | 1 |
| Arrowood, CC | 1 |
| Garrett-Mead, N | 1 |
| Conway, KC | 1 |
| Edmiston, SN | 1 |
| Ollila, DW | 1 |
| Serody, JS | 1 |
| Thomas, NE | 1 |
| Ivy, SP | 1 |
| Agrawal, L | 1 |
| Dees, EC | 1 |
| Abbruzzese, JL | 1 |
| Kosic, M | 1 |
| Paunovic, V | 1 |
| Ristic, B | 1 |
| Mircic, A | 1 |
| Bosnjak, M | 1 |
| Stevanovic, D | 1 |
| Kravic-Stevovic, T | 1 |
| Trajkovic, V | 1 |
| Harhaji-Trajkovic, L | 1 |
| Misra, SK | 1 |
| Kampert, TL | 1 |
| Pan, D | 1 |
| Sinik, L | 1 |
| Minson, KA | 1 |
| Tentler, JJ | 1 |
| Carrico, J | 1 |
| Bagby, SM | 1 |
| Robinson, WA | 1 |
| Kami, R | 1 |
| Burstyn-Cohen, T | 1 |
| Eckhardt, SG | 1 |
| Frye, SV | 1 |
| Earp, HS | 1 |
| DeRyckere, D | 1 |
| Graham, DK | 1 |
| Del Bello, B | 1 |
| Toscano, M | 1 |
| Moretti, D | 1 |
| Maellaro, E | 1 |
| Ghosh, S | 1 |
| Bishayee, K | 1 |
| Khuda-Bukhsh, AR | 1 |
| Hiramoto, K | 1 |
| Murata, T | 2 |
| Shimizu, K | 2 |
| Morita, H | 2 |
| Inui, M | 2 |
| Manganiello, VC | 1 |
| Tagawa, T | 2 |
| Arai, N | 1 |
| Lee, KW | 1 |
| Ryu, HW | 1 |
| Oh, SS | 1 |
| Park, S | 1 |
| Madhi, H | 1 |
| Yoo, J | 1 |
| Park, KH | 1 |
| Kim, KD | 1 |
| Hayashi, T | 1 |
| Chan, M | 1 |
| Norton, JT | 1 |
| Wu, CC | 1 |
| Yao, S | 1 |
| Cottam, HB | 1 |
| Tawatao, RI | 1 |
| Corr, M | 1 |
| Carson, DA | 1 |
| Daniels, GA | 1 |
| Martin, L | 1 |
| Jiang, YY | 1 |
| Yang, R | 1 |
| Wang, HJ | 1 |
| Huang, H | 1 |
| Wu, D | 1 |
| Tashiro, S | 1 |
| Onodera, S | 1 |
| Ikejima, T | 1 |
| Hammerová, J | 1 |
| Uldrijan, S | 1 |
| Táborská, E | 1 |
| Vaculová, AH | 1 |
| Slaninová, I | 1 |
| Okumura, K | 1 |
| Cohen, Y | 1 |
| Rosenbaum, E | 1 |
| Begum, S | 1 |
| Goldenberg, D | 1 |
| Esche, C | 1 |
| Lavie, O | 1 |
| Sidransky, D | 1 |
| Westra, WH | 1 |
| Berrahmoune, H | 1 |
| Herbeth, B | 1 |
| Lamont, JV | 1 |
| Masson, C | 1 |
| FitzGerald, SP | 1 |
| Visvikis-Siest, S | 1 |
| Imperatori, L | 1 |
| Damia, G | 1 |
| Taverna, P | 1 |
| Garattini, E | 1 |
| Citti, L | 1 |
| Boldrini, L | 1 |
| D'Incalci, M | 1 |
| Braybrooke, JP | 1 |
| Houlbrook, S | 1 |
| Crawley, JE | 1 |
| Propper, DJ | 1 |
| O'Byrne, KJ | 1 |
| Stratford, IJ | 1 |
| Harris, AL | 1 |
| Shuker, DE | 1 |
| Talbot, DC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers With Response and Resistance[NCT02581930] | Phase 2 | 18 participants (Actual) | Interventional | 2016-08-17 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Antitumor response defined as the sum of complete response (CR) and partial response (PR). CR is the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm (<1 cm). PR is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. (NCT02581930)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Ibrutinib) | 0 |
Estimated using the Kaplan Meier method. (NCT02581930)
Timeframe: Duration of time from day 1 of treatment to death as a result of any cause, assessed up to 1 year
| Intervention | months (Median) |
|---|---|
| Treatment (Ibrutinib) | 6 |
Progression free survival (PFS) is defined as the duration of time from Day 1 of treatment to time of progression (based on clinical or radiographic grounds) or death as a result of any cause, whichever occurs first. (NCT02581930)
Timeframe: 1 year
| Intervention | months (Median) |
|---|---|
| Treatment (Ibrutinib) | 1.3 |
1 review available for adenine and Melanoma
| Article | Year |
|---|---|
[What's new in dermatological treatments?].
Topics: Adenine; Anti-HIV Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic | 2010 |
1 trial available for adenine and Melanoma
| Article | Year |
|---|---|
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922).
Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Humans; Interleukin-2; Male; Melanoma; Melanoma, Cu | 2021 |
18 other studies available for adenine and Melanoma
| Article | Year |
|---|---|
Discovery of novel ibrutinib analogues to treat malignant melanoma.
Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell P | 2021 |
Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells.
Topics: Adenine; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; D | 2022 |
Photodynamic therapy enhances skin cancer chemotherapy effects through autophagy regulation.
Topics: Adenine; Aminolevulinic Acid; Autophagy; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferat | 2019 |
3-Methyladenine prevents energy stress-induced necrotic death of melanoma cells through autophagy-independent mechanisms.
Topics: Adenine; AMP-Activated Protein Kinases; Animals; Autophagy; Cell Death; Deoxyglucose; JNK Mitogen-Ac | 2021 |
Nano-Assembly of Pamitoyl-Bioconjugated Coenzyme-A for Combinatorial Chemo-Biologics in Transcriptional Therapy.
Topics: Adenine; Antineoplastic Agents; Cell Line, Tumor; Coenzyme A; Drug Carriers; Humans; Melanoma; Nanop | 2018 |
Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma.
Topics: Adenine; Animals; Azetidines; c-Mer Tyrosine Kinase; Cell Line, Tumor; Cell Proliferation; Cell Surv | 2019 |
Cisplatin-induced apoptosis inhibits autophagy, which acts as a pro-survival mechanism in human melanoma cells.
Topics: Adaptor Proteins, Vesicular Transport; Adenine; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2013 |
Graveoline isolated from ethanolic extract of Ruta graveolens triggers apoptosis and autophagy in skin melanoma cells: a novel apoptosis-independent autophagic signaling pathway.
Topics: Adenine; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Line, Tumor; Humans; Me | 2014 |
Role of phosphodiesterase 2 in growth and invasion of human malignant melanoma cells.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Adenine; Cell Line, Tumor; Cell Movement; Cell Proliferation | 2014 |
Depigmentation of α-melanocyte-stimulating hormone-treated melanoma cells by β-mangostin is mediated by selective autophagy.
Topics: Adenine; alpha-MSH; Animals; Autophagy; Cell Survival; Garcinia mangostana; Humans; Inflammation; Me | 2017 |
Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2.
Topics: Adenine; Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Synergism; Female; Flow C | 2011 |
Mechanism of autophagy induction and role of autophagy in antagonizing mitomycin C-induced cell apoptosis in silibinin treated human melanoma A375-S2 cells.
Topics: Adenine; Apoptosis; Autophagy; Cell Line, Tumor; Down-Regulation; Humans; Melanoma; Mitomycin; NF-ka | 2011 |
Necroptosis modulated by autophagy is a predominant form of melanoma cell death induced by sanguilutine.
Topics: Adenine; Antineoplastic Agents; Autophagy; Benzophenanthridines; Caspases; Cell Line, Tumor; Cell Su | 2012 |
Characterization of phosphodiesterase 2A in human malignant melanoma PMP cells.
Topics: Adenine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclic Nucleotide Phosphodiesterases, Typ | 2013 |
Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites.
Topics: Adenine; DNA; Exons; Head and Neck Neoplasms; Humans; Melanocytes; Melanoma; Models, Genetic; Mutage | 2004 |
Lack of association between EGF 61A>G polymorphism and plasma EGF concentration in the STANISLAS family study.
Topics: Adenine; Epidermal Growth Factor; Guanine; Humans; Melanoma; Osmolar Concentration; Polymorphism, Ge | 2007 |
3T3 NIH murine fibroblasts and B78 murine melanoma cells expressing the Escherichia coli N3-methyladenine-DNA glycosylase I do not become resistant to alkylating agents.
Topics: 3T3 Cells; Adenine; Alkylating Agents; Animals; Drug Resistance; Escherichia coli; Gene Expression R | 1994 |
Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen.
Topics: Adenine; Adult; Aged; Antineoplastic Agents, Alkylating; Comet Assay; Dacarbazine; DNA Damage; Femal | 2000 |